Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry
نویسندگان
چکیده
Abstract Background Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments. Nonetheless, effect other lipid parameters, as remnants or, so-called residual risk, are unknown. Methods Multicenter and retrospective registry patients treated with PCSK9 inhibitors from 14 different hospitals Spain. Before on-treatment parameters were recorded. Cholesterol calculated equation: total minus LDLc HDLc values ≥30 considered high. Residual risk was estimated 1) estimation LDL particle size, triglycerides/HDLc ratio (TG/HDL) <2 assumed low dense particles; 2) cholesterol/HDLc (TC/HDL) >3 high; and; 3) triglycerides-to-glucose (TG/Gluc) index, obtained natural logarithm (triglycerides * glucose/2) Results A 652 analyzed, mean age 60.0 (10.5) years 161 (24.69%) women. Baseline 149.2 (49.9) mg/dl, 29.9 (20.3) TG/HDL 3.9 (4.1), TC/HDL 4.9 (1.9) TG/Gluc index 8.9 (0.7). Most (92.3%) on statins; 54.8% ezetimibe, 8.5% fibrates. Evolocumab initiated in 318 (56.6%) patients; 229 (40.7%) alirocumab 75 mg 15 (2.7%) 150 mg. Median time to second blood determination 187.5 (IQR 101–242) days. Mean 67.46 (45.78) mg/dl what represented a 55% reduction. As shown figure, significant reduction (p=0.017), (p=0.020), (p<0.001) (p<0.001). The percentage >30 decreased: 34.62% 30.07 (p<0.01). Significant reductions also observed >2 (71.25% 61.98%; p<0.01) or (94.28% 38.97%; Conclusions This multicenter real-world demonstrates positive lipid-residual beyond reductions. Funding Acknowledgement Type funding sources: None.
منابع مشابه
PCSK9 inhibitors: A new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events. However,...
متن کاملThe effect of Policosanol on decrease of cholesterol, triglyceride and the other lipid metabolite levels in blood of Wistar rats
Background & Aim: Policosanol is a component from main alcohol groups with long-chain that extracted from cane sugar. In the present research, the effect of policosanol was investigated on decrease of lipid metabolite levels in blood of hypercholesterolemia rats. Experimental: A number of 32 male Wistar rats race with average weight of 250 g was divided into four groups including negative cont...
متن کاملLipid Lowering Therapy and Circulating PCSK9 Concentration
Hypercholesterolemia, particularly an increase in low-density lipoprotein cholesterol (LDL-C) levels, contributes substantially to the development of coronary artery disease and the risk for cardiovascular events. As the first-line pharmacotherapy, statins have been shown to reduce both LDL-C levels and cardiovascular events. However, despite intensive statin therapy, a sizable proportion of st...
متن کاملThe effect of Policosanol on decrease of cholesterol, triglyceride and the other lipid metabolite levels in blood of Wistar rats
Background & Aim: Policosanol is a component from main alcohol groups with long-chain that extracted from cane sugar. In the present research, the effect of policosanol was investigated on decrease of lipid metabolite levels in blood of hypercholesterolemia rats. Experimental: A number of 32 male Wistar rats race with average weight of 250 g was divided into four groups including negative cont...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2022
ISSN: ['2634-3916']
DOI: https://doi.org/10.1093/eurheartj/ehac544.2368